scholarly article | Q13442814 |
P2093 | author name string | Pitsucha Sanguanwit | |
Preecha Montakantikul | |||
Jetjamnong Sueajai | |||
Pitchaya Dilokpattanamongkol | |||
Saranya Auparakkitanon | |||
Tospon Lertwattanachai | |||
Viratch Tangsujaritvijit | |||
P2860 | cites work | The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents | Q26823328 |
Unrevealing culture-negative severe sepsis | Q26830520 | ||
Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients | Q33552161 | ||
Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy | Q33821554 | ||
Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units | Q35607715 | ||
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams | Q35908084 | ||
Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance | Q36089167 | ||
Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia | Q36866920 | ||
An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy | Q37563029 | ||
Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance. | Q38705266 | ||
Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome | Q38820842 | ||
The immune system's role in sepsis progression, resolution, and long-term outcome | Q38991057 | ||
Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. | Q39015165 | ||
Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? | Q39344408 | ||
Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study | Q41741255 | ||
Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. | Q42654588 | ||
Maximally effective dosing regimens of meropenem in patients with septic shock. | Q47624900 | ||
Mechanisms and treatment of organ failure in sepsis. | Q52565424 | ||
Sepsis in European intensive care units: results of the SOAP study. | Q54471944 | ||
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients? | Q57237700 | ||
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections | Q57289588 | ||
Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients | Q88271342 | ||
Sepsis and septic shock | Q89222248 | ||
Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis | Q90612119 | ||
Post-sepsis syndrome - an evolving entity that afflicts survivors of sepsis | Q92354721 | ||
Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: a prospective observational study | Q93185288 | ||
P921 | main subject | sepsis | Q183134 |
meropenem | Q421670 | ||
septic shock | Q1765564 | ||
P304 | page(s) | 26 | |
P577 | publication date | 2020-04-15 | |
P1433 | published in | Journal of intensive care | Q27725973 |
P1476 | title | Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial | |
P478 | volume | 8 |
Search more.